Meloxicam Indications
Meloxicam is used for the symptomatic treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, with typical dosing of 7.5-15 mg once daily.
Primary Approved Indications
Meloxicam is a COX-2 preferential NSAID indicated for:
- Osteoarthritis (OA) - Most extensively studied indication, with proven efficacy at 7.5-15 mg daily 1, 2
- Rheumatoid arthritis (RA) - Effective for inflammatory joint pain and stiffness 1, 3
- Ankylosing spondylitis - Approved for this inflammatory spinal condition 1, 4
- Juvenile idiopathic arthritis - Pediatric inflammatory arthritis 1
Dosing Framework
The standard approach is:
- Starting dose: 7.5 mg once daily
- Maximum dose: 15 mg daily (7.5 mg maximum in elderly patients) 1
- Alternative routes: Rectal suppository at similar doses, or intramuscular injection (1.5 mL for 3-5 days) followed by oral therapy 5, 1
Clinical Context and Safety Profile
Meloxicam's COX-2 preferential activity at therapeutic doses provides anti-inflammatory and analgesic effects comparable to traditional NSAIDs (diclofenac, piroxicam, naproxen) but with significantly lower gastrointestinal toxicity 3, 4, 2. In clinical trials, GI adverse events and dropout rates were comparable to placebo and lower than diclofenac 2.
Important Prescribing Considerations
The drug appears in NSAID prescribing guidelines 6 with standard NSAID precautions:
- GI bleeding risk: Age-dependent (1 in 2,100 in patients <45 years vs. 1 in 110 in patients >75 years)
- Cardiovascular effects: Use caution in patients with hypertension or cardiovascular risk
- Renal impairment: Avoid in patients with existing renal disease
- Drug interactions: Increased bleeding risk when combined with anticoagulants (3-6 fold increase)
When to Add Gastroprotection
Based on appropriateness criteria 7:
- Patients <65 years with no GI history: meloxicam alone is appropriate
- Patients ≥65 years or with GI risk factors: add proton pump inhibitor
- Patients on aspirin, steroids, or warfarin: add PPI regardless of age
Common Pitfalls
- Underdosing: The 3.75 mg dose did not consistently achieve statistical significance for all endpoints in OA trials; start at 7.5 mg 2
- Elderly dosing: Maximum 7.5 mg daily in elderly patients, not 15 mg 1
- Cardiovascular assumptions: While COX-2 preferential, meloxicam shows peripheral edema and hypertension at rates similar to traditional NSAIDs 4